THURSDAY, MAY 4

15:00-17:00  Educational Session: Genomics  
Grand Ballroom I & II

Session Chair: Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada

15:00-15:20  Molecular tumor board - Case presentation  
Lillian L. Siu and William C. Hahn

15:20-15:55  Clinical applications: Drug access and design of genotype-specific trials  
Lillian L. Siu

15:55-16:30  Opportunities for translational and discovery research: Next-Gen genomics  
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA

16:30-17:00  Panel discussion/Questions from audience  
Lillian L. Siu and William C. Hahn

17:00-17:30  Break  
Grand Ballroom Foyer

17:30-18:00  Welcome and Opening Remarks  
Grand Ballroom I & II

Margaret Foti, American Association for Cancer Research, Philadelphia, PA
Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN
Carlos Gil M. Ferreira, D’or Institute for Research and Education, Rio de Janeiro, Brazil

18:00-19:30  Plenary Session 1: Immune Checkpoints: Successes and What We Have Learned  
Grand Ballroom I & II

Session Chair: João P.B. Viola, Brazilian National Cancer Institute, Rio de Janeiro, Brazil

18:00-18:30  Selective pressure by activated T cells identifies de novo and adaptive resistance mechanisms in melanoma  
Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA

18:30-19:00  State of clinical success of immune checkpoints (new preclinical data on anti-PD-1 and anti-PDL-1)  
Cristina B. Bonorino, Pontificia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil

19:00-19:30  ER stress responses as new immune checkpoints in cancer  
Juan R. Cubillos-Ruiz, Weill Cornell Medical College, New York, NY

19:45-21:30  Opening Reception  
Grand Ballroom III and Foyer
FRIDAY, MAY 5

08:30-09:15  Keynote Lecture 1  
Grand Ballroom I & II  

Session Chair: Carlos Gil M. Ferreira, D’or Institute for Research and Education, Rio de Janeiro, Brazil  
The different facets of cervical cancer prevention  
Luisa L. Villa, Fundação Faculdade de Medicina de São Paulo, São Paulo, Brazil

09:15-09:45  Break  
Grand Ballroom Foyer

09:45-10:45  Plenary Session 2: Tumor Heterogeneity  
Grand Ballroom I & II  

Session Chair: Felipe C. Geyer, Memorial Sloan Kettering Cancer Center, New York, NY  

9:45-10:15  The dynamics of cancer cell heterogeneity  
Guido Lenz, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

10:15-10:45  Intratumor genetic heterogeneity  
Felipe C. Geyer

10:45-11:00  Break  
Grand Ballroom Foyer

11:00-12:30  Plenary Session 3: Hematologic Malignancies  
Grand Ballroom I & II  

Session Chair: Eliana Abdelhay, Brazilian National Cancer Institute, Rio de Janeiro, Brazil  

11:00-11:30  Epigenetic mechanisms in pathogenesis and targeted therapy for B-cell lymphomas  
Ari M. Melnick, Weill Cornell Medical College, New York, NY

11:30-12:00  Clinical networking as a tool for improvement of leukemia care and research in developing countries: The experience of the International Consortium on Acute Leukemias (ICAL)  
Eduardo Magalhães Rego, University of São Paulo, São Paulo, Brazil

12:00-12:30  Novel therapeutic targets in multiple myeloma  
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA
12:30 - 15:00  Poster Session A/Lunch
Grand Ballroom III and Foyer

15:15-16:45  Plenary Session 4: Precision Medicine/Targeted and Combination Therapies/Drug Resistance
Grand Ballroom I & II

Session Chair: Oscar G. Arrieta, Instituto Nacional de Cancerología, Mexico City, Mexico

15:15-15:45  A systems approach to rational combination therapy with PARP inhibitors
Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, TX

15:45-16:15  Overcoming drug resistance and tumor heterogeneity in gastrointestinal cancers
Ryan B. Corcoran, Massachusetts General Hospital Cancer Center, Boston, MA

16:15-16:45  Evolution and clinical impact of co-occurring genetic alterations in lung cancer
Trever G. Bivona, University of California, San Francisco, CA

16:45-17:00  Break
Grand Ballroom Foyer

17:00-18:30  Plenary Session 5: Liquid Biopsies/Organoids/PDX
Grand Ballroom I & II

Session Chair: Andrés F. Cardona, Fundación Santa Fe de Bogotá, Bogotá, Colombia

17:00-17:30  Circulating tumor DNA as a “liquid biopsy” for precision medicine: Basic concepts
Anamaria A. Camargo, Ludwig Institute for Research on Cancer, São Paulo, Brazil

17:30-18:00  Cancer evolution as a therapeutic target
Alberto Bardelli, University of Turin School of Medicine, Candiolo, Italy

18:00-18:30  Patient-derived xenografts and organoids to predict therapeutic response for breast cancer patients
Alana L. Welm, University of Utah Huntsman Cancer Institute, Salt Lake City, UT

18:30-  Evening Off/Dinner on Own
SATURDAY, MAY 6

08:30-09:15  Keynote Lecture 2
Grand Ballroom I & II

Session Chair: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN
Defining a cancer dependencies map
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA

09:15-09:45  Break
Grand Ballroom Foyer

09:45-11:15  Plenary Session 6: DNA Repair and PARP Inhibitors
Grand Ballroom I & II

Session Chair: Dyelson Antonow, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil

09:45-10:15  Targeting DNA repair in cancer therapy
Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, MA

10:15-10:45  PARP trapping and Schlafen 11 to kill cancer cells
Yves G. Pommier, National Cancer Institute-CCR, Bethesda, MD

10:45-11:15  Methods for defining DNA repair defects in human cancer
Simon N. Powell, Memorial Sloan Kettering Cancer Center, New York, NY

11:15-11:30  Break
Grand Ballroom Foyer

11:30-13:00 pm  Plenary Session 7: Hormone-Dependent Cancers and Steroid Receptors
Grand Ballroom I & II

Session Chair: Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil

11:30-12:00  Lessons for ER+ breast cancer from neoadjuvant endocrine therapy trials
Matthew J. Ellis, Baylor College of Medicine, Houston, TX

12:00-12:30  Targeting DNA repair dysfunction in prostate cancer
Karen E. Knudsen, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA

12:30-13:00  Targeting DNA repair deficiencies in breast cancer
Samuel Aparicio, BC Cancer Research Centre, Vancouver, BC, Canada

13:00-15:00  Poster Session B/Lunch
Grand Ballroom III and Foyer
15:15-16:45  **Plenary Session 8: Oncogenes and Tumor Suppressors**  
Grand Ballroom I & II  

**Session Chair: Roger Chammas**, University of São Paulo, São Paulo, Brazil  

15:15-15:45  Strategies to prevent and treat resistance to EGFR inhibitors in lung cancer  
Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA  

15:45-16:15  Tumor suppressor and tumor maintenance genes  
Scott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, NY  

16:15-16:45  Long noncoding RNA-mediated RNA editing as a new mechanism of tumor suppressor gene inactivation  
Emmanuel Dias-Neto, A.C. Camargo Cancer Center, São Paulo, Brazil  

16:45-17:00  Break  
Grand Ballroom Foyer  

17:00-18:30  **Plenary Session 9: Epigenetics**  
Grand Ballroom I & II  

**Session Chair: Paulo M. Hoff**, Centro de Oncologia, São Paulo, Brazil  

17:00-17:30  Title to be announced  
Daniel De Carvalho, Princess Margaret Cancer Centre, Toronto, ON, Canada  

17:30-18:00  The promise among the setbacks for epigenetic therapy in solid tumors  
Nilofer S. Azad, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD  

18:00-18:30  Defining cancer specific epigenomic signature associated with glioma progression  
Houtan Noushmehr, University of São Paulo, Ribeirao Preto, Brazil  

18:30-18:45  **Closing Remarks**  
Grand Ballroom I & II  

Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN  
Carlos Gil M. Ferreira, D’or Institute for Research and Education, Rio de Janeiro, Brazil